Trump's Generic Drug Tariff Plan: Zero Now, 200% Later — India in the Crosshairs
US President Donald Trump announced zero tariffs on imported generic medicines for two years, followed by 100% tariffs from August 2028, with the aim of bringing pharmaceutical manufacturing back to the US. India is a major exporter of generic drugs to the US, and the policy may significantly impact Indian pharma companies. Trump said the goal is to protect American consumers and onshore production.
Why It Matters
India supplies a huge share of generic medicines to the US. This tariff plan could hit Indian pharma exports hard, affecting companies, jobs, and potentially drug prices for American patients who rely on affordable Indian generics.
🔒 Potential Impact + source link
Subscribe to unlock the impact analysis and original source for every story.